Form 8-K Immune Therapeutics, For: Jan 21
�
�
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
�
FORM 8-K
��
CURRENT REPORT
Pursuant to Section�13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2015
��
Immune Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
�
�
�
Florida | 000-54933 | 59-3226705 |
(State or other jurisdiction | (Commission | (IRS Employer |
or incorporation) | File Number) | Identification Number) |
� | � | � |
�
��
37 North Orange Avenue, Suite 607, Orlando, Florida | 32801 |
(Address of principal executive offices) | (Zip Code) |
�
�
(888) 613 - 8802
(Registrant’s telephone number, including area code)
�
�
______________________________________________
Former name or former address, if changed since last report
�
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
�
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
�
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
�
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
�
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
�
�
(1) |
� |
�
�
Item 8.01 Other Events.
�
ClearTrust, LLC is our new transfer agent and shareholder provider. ClearTrust, LLC acquired all issuer accounts of our former transfer agent, Guardian Registrar & Transfer, Inc. As a result, effective January 21, 2015, ClearTrust, LLC became our transfer agent. All of the directly held shares of common stock of our shareholders were transferred from Guardian Registrar & Transfer, Inc. to ClearTrust, LLC’s platform. A copy of the letter to our shareholders regarding this change is attached hereto as Exhibit 99.1 and incorporated herein by reference.
�
Item 9.01. Financial Statements and Exhibits.
�
(d) Exhibits
�
�
� | Exhibit No. | Description |
� | � | � |
� | 99.1 | Shareholder Letter Regarding Transfer Agent Change |
�
�
(2) |
� |
�
�
�
SIGNATURE
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
�
�
� | � | Immune Therapeutics, Inc. |
� | � | � |
� | � | By: /s/ Noreen Griffin |
� | � | Noreen Griffin, Chief Executive Officer |
�
�
�
Date: January 26, 2015
�
EXHIBIT INDEX
�
�
� | Exhibit No. | Description |
� | � | � |
� | 99.1 | Shareholder Letter Regarding Transfer Agent Change |
�
�
�
�
�
�
�
�
Exhibit 99.1
�
January 26, 2015
�
ClearTrust, LLC is Immune Therapeutics’
New Transfer Agent and Support Provider
�
No Action Required of Shareholders for this Transaction
�
�
�
Dear Immune Therapeutics, Inc. Shareholder:
�
I am writing today to update you on an important operational change. ClearTrust, LLC, a leading stock transfer agent serving growth companies and community banks, has acquired all issuer accounts of Guardian Registrar & Transfer, Inc., our transfer agent. As a result, ClearTrust is now Immune Therapeutics’ transfer agent and shareholder support provider.
�
This change includes the transfer of your directly held shares of Immune Therapeutics’ common stock from Guardian Registrar & Transfer to ClearTrust’s platform. There is no action required on your part for this transaction.
�
If you have any questions regarding your shares, please contact a ClearTrust specialist by telephone at (813) 235-4490 or email at [email protected]. If you need to send documents to ClearTrust, such documents can be emailed to the foregoing email address, faxed to (813) 388-4549 or mailed to 16540 Pointe Village Drive, Suite 210, Lutz, Florida 33558.
�
�
Thank you for your continued support of Immune Therapeutics.
�
�
� | Sincerely, | |
� | � | � |
� | � | � |
� | � | Noreen Griffin |
� | � | Chief Executive Officer |
�
�
�
37 North Orange Ave, Suite 607, Orlando, FL 32801
(888) 613-8802 Fax: (866) 514-8807
www.immunetherapeutics.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MidFirst Bank’s 1st Century Division Donates $250,000 to Saint John’s Health Center
- Correction: Solutions30, through its subsidiary Unit-T, is selected to support Fluvius in their ´Energy Grid upgrade program´ in Flanders with a 5-year contract, extendable for another 3 years
- WestPark Announces Closing of a $6,000,000 Initial Public Offering for CDT Environmental (NASDAQ: CDTG)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!